Cancer-testis Antigen FATE1 Expression in Adrenocortical Tumors Is Associated with A Pervasive Autoimmune Response and Is A Marker of Malignancy in Adult, but Not Children, ACC.

adrenocortical carcinoma autoantibodies cancer-testis antigens immune response

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
14 Mar 2020
Historique:
received: 29 01 2020
revised: 04 03 2020
accepted: 11 03 2020
entrez: 19 3 2020
pubmed: 19 3 2020
medline: 19 3 2020
Statut: epublish

Résumé

The SF-1 transcription factor target gene

Identifiants

pubmed: 32183347
pii: cancers12030689
doi: 10.3390/cancers12030689
pmc: PMC7140037
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Agence Nationale de la Recherche
ID : 15-CE14-0017-01

Références

Nat Genet. 2014 Jun;46(6):607-12
pubmed: 24747642
Nat Rev Cancer. 2005 Aug;5(8):615-25
pubmed: 16034368
J Clin Endocrinol Metab. 2010 Mar;95(3):1458-62
pubmed: 20080844
Endocr Rev. 2014 Apr;35(2):282-326
pubmed: 24423978
Clin Cancer Res. 2016 Dec 15;22(24):6247-6255
pubmed: 27307598
Front Endocrinol (Lausanne). 2015 Feb 18;6:23
pubmed: 25741319
Kidney Int. 2019 Mar;95(3):666-679
pubmed: 30784662
Transl Oncol. 2019 May;12(5):733-738
pubmed: 30877975
Nat Commun. 2015 Mar 06;6:6302
pubmed: 25743702
Mol Endocrinol. 2007 Dec;21(12):2968-87
pubmed: 17761949
Eur J Cancer. 2006 May;42(8):1040-3
pubmed: 16574405
Clin Chim Acta. 2013 Jun 5;421:213-8
pubmed: 23541686
Cancer Cell. 2016 May 9;29(5):723-736
pubmed: 27165744
J Immunother Cancer. 2018 Jun 22;6(1):63
pubmed: 29929551
J Oncol. 2019 Apr 1;2019:6072863
pubmed: 31057613
Cancers (Basel). 2019 Nov 05;11(11):
pubmed: 31694270
Surgery. 2013 Dec;154(6):1405-16; discussion 1416
pubmed: 24238056
J Clin Endocrinol Metab. 2010 Oct;95(10):E161-71
pubmed: 20660055
J Immunother Cancer. 2018 Oct 22;6(1):111
pubmed: 30348224
Oncoimmunology. 2019 Aug 28;8(11):e1655362
pubmed: 31646101
J Am Soc Nephrol. 2018 May;29(5):1536-1548
pubmed: 29555830
Mol Cell Biol. 2019 Jun 27;39(14):
pubmed: 31036566
Front Endocrinol (Lausanne). 2016 Mar 29;7:24
pubmed: 27065945
Nature. 2007 Apr 12;446(7137):815-9
pubmed: 17429401
Br J Cancer. 2005 Aug 22;93(4):387-91
pubmed: 16106245
Clin Cancer Res. 2009 Jan 15;15(2):668-76
pubmed: 19147773
Immunity. 2018 Apr 17;48(4):812-830.e14
pubmed: 29628290
J Immunother Cancer. 2015 Feb 17;3:3
pubmed: 25767716
Lab Invest. 2005 Feb;85(2):205-13
pubmed: 15580283
Endocr Connect. 2018 Dec;7(12):E5-E8
pubmed: 30400026
Nat Commun. 2015 Nov 16;6:8840
pubmed: 26567849
EMBO Rep. 2016 Sep;17(9):1264-80
pubmed: 27402544
Br J Cancer. 2003 Jul 21;89(2):291-7
pubmed: 12865919
J Clin Oncol. 2009 Mar 1;27(7):1108-15
pubmed: 19139432

Auteurs

Mabrouka Doghman-Bouguerra (M)

Institut de Pharmacologie Moléculaire et Cellulaire, Université Côte d'Azur, CNRS, 660 route des Lucioles-Sophia Antipolis, 06560 Valbonne, France.
NEOGENEX-CANCER CNRS International Associated Laboratory, 660 route des Lucioles, Sophia Antipolis, 06560 Valbonne, France; 1532 Av. Silva Jardim, Curitiba PR 80250-200, Brazil.

Pascal Finetti (P)

Laboratoire d'Oncologie Prédictive, CRCM, Institut Paoli-Calmettes, INSERM UMR1068, CNRS UMR7258, Aix-Marseille Université, 232 Bd. Ste-Marguerite, 13009 Marseille, France.

Nelly Durand (N)

Institut de Pharmacologie Moléculaire et Cellulaire, Université Côte d'Azur, CNRS, 660 route des Lucioles-Sophia Antipolis, 06560 Valbonne, France.
NEOGENEX-CANCER CNRS International Associated Laboratory, 660 route des Lucioles, Sophia Antipolis, 06560 Valbonne, France; 1532 Av. Silva Jardim, Curitiba PR 80250-200, Brazil.

Ivy Zortéa S Parise (IZS)

NEOGENEX-CANCER CNRS International Associated Laboratory, 660 route des Lucioles, Sophia Antipolis, 06560 Valbonne, France; 1532 Av. Silva Jardim, Curitiba PR 80250-200, Brazil.
Department, Pelé Pequeno Principe Research Institute, 1532 Av. Silva Jardim, Curitiba PR 80250-200, Brazil.

Silviu Sbiera (S)

Division of Endocrinology and Diabetes, Department of Internal Medicine I, University Hospital, University of Würzburg, 2 Josef-Schneider-Straße, 97080 Würzburg, Germany.
Comprehensive Cancer Center Mainfranken, University of Würzburg, 6 Josef-Schneider-Straße, 97080 Würzburg, Germany.

Giulia Cantini (G)

Endocrinology Unit, Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, 6 viale Pieraccini, 50139 Florence, Italy.

Letizia Canu (L)

Endocrinology Unit, Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, 6 viale Pieraccini, 50139 Florence, Italy.

Ségolène Hescot (S)

Service de Médecine Nucléaire, Institut Curie, 35 rue Dailly, 92210 Saint Cloud, France.

Mirna M O Figueiredo (MMO)

NEOGENEX-CANCER CNRS International Associated Laboratory, 660 route des Lucioles, Sophia Antipolis, 06560 Valbonne, France; 1532 Av. Silva Jardim, Curitiba PR 80250-200, Brazil.
Department, Pelé Pequeno Principe Research Institute, 1532 Av. Silva Jardim, Curitiba PR 80250-200, Brazil.

Heloisa Komechen (H)

NEOGENEX-CANCER CNRS International Associated Laboratory, 660 route des Lucioles, Sophia Antipolis, 06560 Valbonne, France; 1532 Av. Silva Jardim, Curitiba PR 80250-200, Brazil.
Department, Pelé Pequeno Principe Research Institute, 1532 Av. Silva Jardim, Curitiba PR 80250-200, Brazil.

Iuliu Sbiera (I)

Division of Endocrinology and Diabetes, Department of Internal Medicine I, University Hospital, University of Würzburg, 2 Josef-Schneider-Straße, 97080 Würzburg, Germany.
Comprehensive Cancer Center Mainfranken, University of Würzburg, 6 Josef-Schneider-Straße, 97080 Würzburg, Germany.

Gabriella Nesi (G)

Division of Pathological Anatomy, Department of Health Sciences, University of Florence, 6 viale Pieraccini, 50139 Florence, Italy.

Angelo Paci (A)

Department of Neuro-Endocrine Tumors, Institut Gustave Roussy, 114 rue Edouard Vaillant, 94800 Villejuif, France.

Abir Al Ghuzlan (A)

Department of Neuro-Endocrine Tumors, Institut Gustave Roussy, 114 rue Edouard Vaillant, 94800 Villejuif, France.

Daniel Birnbaum (D)

Laboratoire d'Oncologie Prédictive, CRCM, Institut Paoli-Calmettes, INSERM UMR1068, CNRS UMR7258, Aix-Marseille Université, 232 Bd. Ste-Marguerite, 13009 Marseille, France.

Eric Baudin (E)

Department of Neuro-Endocrine Tumors, Institut Gustave Roussy, 114 rue Edouard Vaillant, 94800 Villejuif, France.

Michaela Luconi (M)

Endocrinology Unit, Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, 6 viale Pieraccini, 50139 Florence, Italy.

Martin Fassnacht (M)

Division of Endocrinology and Diabetes, Department of Internal Medicine I, University Hospital, University of Würzburg, 2 Josef-Schneider-Straße, 97080 Würzburg, Germany.
Comprehensive Cancer Center Mainfranken, University of Würzburg, 6 Josef-Schneider-Straße, 97080 Würzburg, Germany.

Bonald C Figueiredo (BC)

NEOGENEX-CANCER CNRS International Associated Laboratory, 660 route des Lucioles, Sophia Antipolis, 06560 Valbonne, France; 1532 Av. Silva Jardim, Curitiba PR 80250-200, Brazil.
Department, Pelé Pequeno Principe Research Institute, 1532 Av. Silva Jardim, Curitiba PR 80250-200, Brazil.

François Bertucci (F)

Laboratoire d'Oncologie Prédictive, CRCM, Institut Paoli-Calmettes, INSERM UMR1068, CNRS UMR7258, Aix-Marseille Université, 232 Bd. Ste-Marguerite, 13009 Marseille, France.

Enzo Lalli (E)

NEOGENEX-CANCER CNRS International Associated Laboratory, 660 route des Lucioles, Sophia Antipolis, 06560 Valbonne, France; 1532 Av. Silva Jardim, Curitiba PR 80250-200, Brazil.
Inserm, Institut de Pharmacologie Moléculaire et Cellulaire, 660 route des Lucioles - Sophia Antipolis, 06560 Valbonne, France.

Classifications MeSH